Clinical Trial Update: Study of the Effect of GS-6615 in Subjects With LQT-3 [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating GS-6615 in subjects with Long QT syndrome (LQT-3) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Long Qt Syndrome

Drugs mentioned

• GS-6615

Snippet

Sponsor: Gilead Sciences | Conditions: Long QT Syndrome | Phase 1 | Status: COMPLETED